SCHEMBL3685708

SCHEMBL3685708

CCCN(C(C)COS(=O)(=O)c1ccc(C)cc1)S(=O)(=O)c1sc2ccc(Cl)cc2c1C

nearest known ligand 0.45

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
CMA1 P23946 3/20 0.44
SLC2A1 P11166 1/20 0.43
HTR6 P50406 3/20 0.39
PFKFB3 Q16875 4/20 0.39
PFKFB4 Q16877 4/20 0.39
PSEN1 P49768 6/20 0.37
PSEN2 P49810 6/20 0.37
APH1B Q8WW43 6/20 0.37
NCSTN Q92542 6/20 0.37
APH1A Q96BI3 6/20 0.37
PSENEN Q9NZ42 6/20 0.37
AKR1B1 P15121 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3682220 0.96 NPSR1 (0.42) NPSR1L3MBTL1CMA1SLC2A1HTR6
SCHEMBL13509461 0.85 NPSR1 (0.45) NPSR1L3MBTL1CMA1SLC2A1HTR6
SCHEMBL3686750 0.82 L3MBTL1 (0.47) NPSR1L3MBTL1CMA1SLC2A1HTR6
SCHEMBL13508344 0.81 CMA1 (0.46) NPSR1L3MBTL1CMA1SLC2A1HTR6
SCHEMBL3686964 0.80 NPSR1 (0.45) NPSR1L3MBTL1CMA1SLC2A1HTR6
SCHEMBL3690605 0.78 NPSR1 (0.45) NPSR1L3MBTL1CMA1SLC2A1HTR6
SCHEMBL13508289 0.75 CMA1 (0.45) NPSR1L3MBTL1CMA1SLC2A1HTR6
SCHEMBL13508290 0.75 CMA1 (0.45) NPSR1L3MBTL1CMA1SLC2A1HTR6
SCHEMBL13509463 0.74 SLC2A1 (0.39) NPSR1L3MBTL1CMA1SLC2A1HTR6
SCHEMBL3691091 0.74 PPARD (0.43) CMA1SLC2A1HTR6PFKFB3PFKFB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7655641-B2 Sulfonamide derivatives as PPAR modulators ELI LILLY AND COMPANY (US) 2010-02-02 US disclosed
US-7655641-B2 Sulfonamide derivatives as PPAR modulators ELI LILLY AND COMPANY (US) 2010-02-02 US disclosed
EP-1597248-B1 SULFONAMIDE DERIVATIVES AS PPAR MODULATORS LILLY CO ELI (US) 2007-12-26 EP disclosed
EP-1597248-B1 SULFONAMIDE DERIVATIVES AS PPAR MODULATORS LILLY CO ELI (US) 2007-12-26 EP disclosed
US-20060217433-A1 Sulfonamide derivatives as ppar modulators ELI LILLY AND COMPANY (US) 2006-09-28 US disclosed
EP-1597248-A2 SULFONAMIDE DERIVATIVES AS PPAR MODULATORS ELI LILLY AND COMPANY (US) 2005-11-23 EP disclosed
WO-2004073606-A2 SULFONAMIDE DERIVATIVES AS PPAR MODULATORS ELI LILLY AND COMPANY (US) 2004-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217433-A1 Sulfonamide derivatives as ppar modulators PPARD, PPARA, PPARG NPSR1 466/4885L3MBTL1 4653/4885CMA1 4529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.